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6.1  Introduction
The ovary is the main regulator of female fertility, and its biologic clock is set to 
ensure reproductive success during a definite life stage. According to the evolu-
tionary concept that organisms maximize fitness by promoting production of 
progeny, allocation of resources between reproductive and somatic functions is 
finely regulated during life [1]. Thus, it has been speculated that the premature 
ageing of the ovary when compared with somatic organs might result from 
increased energy demand for maintenance and repair processes in the soma com-
partment during ageing [1].
According to the human biologic clock, the gradual loss of female fertility 
becomes more dramatic in the late 30s with a steep decrease beginning after age 35, 
ending in menopause at mean age of 51 years [2]. This would preserve women from 
the physical stress of pregnancy in advanced age and maximize the length of time 
they can bear children [3]. As a result, increasing postponement of the first preg-
nancy represents a crucial factor in the widespread of subfertility in industrialized 
societies [4]. Given the intrapopulation variability of the reproductive life span [5], 
it is generally accepted that coping with this issue requires a careful reproductive 
counselling based on accurate predictive markers.
Ovarian functional decline with ageing has been so far extensively characterized 
in terms of gradual depletion of ovarian follicles and reduced ability to produce 
oocytes competent for fertilization and further development [2]. The analysis of the 
molecular and cellular aspects of follicle ageing would require careful consider-
ation. In fact, oocytes and granulosa cells of primordial follicles might remain in a 
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‘resting’ phase for a long time, thus behaving as post-mitotic cells which can be 
required to start growing after 10–50 years. Furthermore, both primordial and grow-
ing follicles become exposed to environmental factors related to the ageing of the 
ovarian somatic compartment, and finally, the development of a competent oocyte 
intimately depends on the crosstalk between all compartments in the ovary.
For decades, research on reproductive ageing has been focusing on the so-called 
quantitative aspect of ovarian ageing, which has led to mathematical models pre-
dicting follicle loss on the basis of chronologic age without taking into account 
biologic markers [6]. When the concept of oocyte ageing as the main determinant of 
fertility decline has become clear [7], researchers have begun to expand investiga-
tions into the whole ovarian microenvironment in search of age-related changes 
with potential effects on follicle and oocyte competence.
Although it is generally accepted that ageing is a result of both inborn and envi-
ronmental factors, most of the numerous theories of ageing share the concept that 
age-associated malfunction results from physiological accumulation of irreparable 
damage to biomolecules as an unavoidable side effect of normal metabolism and 
underline the importance of the capability of defensive repair.
More than a decade after the free radical theory of ovarian ageing first proposed by 
Tarin [8], biological and clinical research has provided numerous evidence that 
increased reactive oxygen species (ROS), which are among the most important physi-
ological inducers of cellular injury associated with ageing [9], is a main determinant to 
follicle ageing [10, 11]. ROS generated by mitochondrial dysfunction is considered the 
main cause for telomere shortening, chromosomal segregation disorders, maturation 
and fertilization failures or oocyte/embryo fragmentation [11]. Looking for ROS aeti-
ology and widespread, a relevant role has been ascribed to advanced glycation end 
products (AGEs), factors that may hamper ovarian stroma vessels, follicular growth, 
assembly of an efficient system of antioxidant enzymatic defence as well as develop-
ment of an efficient perifollicular vascularization [12]. Further evidence for ROS in the 
ovarian follicle was obtained by research on stress signalling pathways in aged granu-
losa and cumulus cells [13, 14]. Enzymatic activity and protein level of superoxide 
dismutase (SOD), the enzyme that reacts with superoxide anion radicals to form oxy-
gen and H2O2, were found to decrease with age, and lower levels of SOD activity are 
associated with unsuccessful IVF outcomes. Nevertheless, there are poor evidences for 
possible benefits from antioxidant treatments in humans, suggesting that further actors 
are involved in modulating stress adaptive response in the ovary during ageing [15].
6.2  Biomarkers
6.2.1  Antral Follicle Count (AFC)
The ovarian AFC and ovarian volume (OV) as determined by transvaginal ultra-
sound examination have been widely evaluated as a marker of ovarian responsive-
ness (OR) [16]. They are reliable indicators of OR and potential predictors of 
menopausal age. The intercycle variation of OV is more pronounced than that of 
AFC. The AFC is the number of antral follicles between 2 and 10 mm in size within 
both ovaries observed on transvaginal ultrasound examination on days 2–3 of the 
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menstrual cycle. The AFC is currently the most reliable ultrasound parameter pre-
dicting age at menopause.
6.2.2  Follicle-Stimulating Hormone (FSH)
FSH is a glycoprotein produced by the anterior pituitary known to regulate the 
recruitment and growth of ovarian follicles from the antral stage to the Graafian fol-
licle and furthermore regulate the androgen conversion to oestrogen. The ovarian 
granulosa cells are the target of FSH.
FSH has been studied extensively as a marker of OR; in fact, elevated levels of 
FSH are the hormonal sign of reproductive ageing. In early follicular phase, FSH 
starts to increase 10 years before menopause; in fact, FSH levels are influenced by 
age and body size [17].
6.2.3  Estradiol (E2)
The levels of E2 show a continuous decline in sex steroids with advancing age; in 
fact, E2 levels show an increase in late menopausal transition.
6.2.4  Luteinizing Hormone (LH)
The LH levels increase with age as a result of increased pituitary sensitivity to 
GnRH. During menopausal transition, LH rises slowly, reaching moderately ele-
vated levels in postmenopause. The increase in FSH levels is more than that in LH, 
because of the loss of inhibin-B and E2 feedback.
6.2.5  Inhibin-B
Inhibin-B is a polypeptide produced by the granulosa and theca cells of the develop-
ing cohort of antral follicles, whereas inhibin-A is primarily a product of the devel-
oping dominant follicle and the corpus luteum. In fact, inhibin-B reflects the ovarian 
follicle pool and may have paracrine functions influencing folliculogenesis in the 
ovary. Inhibin-B correlates with age only during a relatively short time before 
menopausal transition. The levels are influenced by fluctuating ovarian function of 
late ovarian ageing and throughout the menstrual cycle [18].
6.2.6  Anti-Müllerian Hormone (AMH)
AMH is member of the TGF-β superfamily. AMH is produced by the ovarian granu-
losa cells of preantral and small antral follicles, the number of which is related to the 
size of the primordial follicle pool, and serum levels of AMH fluctuate minimally 
throughout the menstrual cycle. AMH is undetectable in the serum until the onset of 
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puberty. AMH modulates primordial follicle recruitment by inhibiting the action of 
FSH on follicle growth and selection. AMH reflects the non-FSH-dependent fol-
licular growth. AMH production disappears during follicular maturation, allowing 
the follicle to complete the development process during FSH-dependent stages of 
growth. AMH secretion is independent of other hormones and is expressed at a 
constant level, irrespective of the day of menstrual cycle. Progressive and linear 
decline until menopause due to a decreasing number of primordial follicle is 
observed [19].
 Conclusions
Ovarian follicles, oocytes and embryos are constantly challenged by stress and 
privations and require adaptive responses for their survival. In addition to redox 
perturbations in the intraovarian microenvironment related to ageing or diseases 
with an oxidative basis, reproductive cells have to face stress conditions during 
manipulation during assisted reproductive procedure [20].
Predicting the age of the final menstrual period for the individual woman 
remains an important goal for clinicians and patients alike. In addition to risk 
assessment, the prediction of the age of menopause may well predict the age of 
subfertility and the end of natural fertility. The biological state of the oocyte 
remains the key element in normal reproduction. The decreasing number of ovar-
ian follicles is accompanied by reduction of oocyte quality. There are many theo-
ries explaining the cause of low-quality oocyte, including abnormal 
vascularization, oxidative stress and imbalance of free radicals; in fact, the for-
mation of AGE is responsible for ageing of the cells. They contribute directly to 
protein damage, induce a chain of reactions of oxidative stress and increase the 
inflammatory reactions. Moreover, this paper stresses the prognostic value of 
clinically used markers evaluating the ovarian reserve, in particular the role of 
AMH, AFC and FSH levels. In conclusion, AMH is the best current available 
measure of ovarian reserve and as predictor of ovarian response to stimulation.
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